

# Factors associated with postoperative quality of life in patients with intertrochanteric fracture

Akam Ramezani, MD, Mazyar Babagoli, MD, Amirhossein Ghaseminejad-Raeini, MD, Mohammadreza Golbakhsh, MD, Seyyed Hossein Shafiei, MD\*

**Introduction:** Intertrochanteric fractures, which make up the majority of hip fractures, are a common and serious injury that can greatly impact quality of life. Treatment of such fractures comprises nearly half of the costs contributed to hip fractures. Identifying the factors affecting the functional outcomes of patients after intertrochanteric fracture can help to reduce burden of disease for the patient and healthcare system. The present study investigated the factors underlying the worsening of short form-36 score (SF-36) scores for intertrochanteric fracture patients.

**Materials and methods:** This retrospective cohort study was designed based on data from our clinic. All consecutive patients with intertrochanteric fractures from November 2016 to September 2020 were reviewed. The exclusion criteria included patients having a second injury or having had previous surgery related to the hip and those with incomplete data. Baseline characteristics of patients were extracted from annotated records. The lab data were acquired from the electronic hospital system. The outcomes were SF-36 scores obtained by phone contact with patients or their families. Statistical analysis was conducted in SPSS.

**Results:** A total of 310 patients were included in the current study. The female gender, advanced age, history of diabetes, thyroid malfunction, cancer, osteoporosis, anticoagulant use and blood transfusion were identified as risk factors for lower SF-36 scores. Low levels of haemoglobin before surgery, blood urea nitrogen (BUN), BUN/Creatinine, and white blood count values correlated with lower SF-36 scores.

**Conclusion:** Numerous contextual variables affected the functional outcomes of the patients. Consideration of these factors could be helpful in reducing costs and improving the quality of life for intertrochanteric fracture patients.

Keywords: elderly, functional outcomes, hip fracture, intertrochanteric fracture, SF-36'

# Introduction

Intertrochanteric fracture is the most common type of extracapsular fracture of the proximal femur which occurs between the greater and the lesser trochanters<sup>[1]</sup>. These devastating injuries account for approximately half of the hip fractures in the elderly population and, in most cases, are related to osteoporosis<sup>[2]</sup>. It has been projected that the number of yearly hip fractures will reach 6.3 million by 2050<sup>[3]</sup>. The cost associated with these fractures is staggering, amounting to a whopping \$2.63 billion in

Orthopedic Surgery Research Center (OSRC), Sina University Hospital, Tehran University of Medical Sciences, Tehran, Iran.

\*Corresponding author. Address: Assistant professor, Orthopedic Surgery Research Center (OSRC), Sina University Hospital, Tehran University of Medical Science, Tehran, Iran, Orthopedic Department, Sina University Hospital, Tehran, Iran. Tel.: +989 126 113 990;. fax: +21 663 485 87. E-mail: dr\_hshafiei@yahoo.com (S. H. Shafiei).

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Received 23 August 2023; Accepted 29 November 2023

http://dx.doi.org/10.1097/MS9.000000000001608

# HIGHLIGHTS

- As intertrochanteric fractures are amongst the most common cases of hip fracture, identifying and controlling the factors affecting the functional outcomes of patients with intertrochanteric fracture can help to reduce burden of disease for the patient and healthcare system.
- As the population is aging, increasing our knowledge about the risk factors for intertrochanteric fracture and its association with negative consequences among the geriatric population, becomes a greater subject of matter.
- Factors such as delayed surgery, anaemia, BUN, BUN/Cr ratio, compromised immune system, advanced age and longer exposure time to anaesthesia, female gender, advanced age, history of diabetes, thyroid malfunction, cancer, osteoporosis, anticoagulant use seemed to be associated with lower short form-36 score scores.

the US annually. This type of hip fracture is responsible for 44% of all hip fracture costs<sup>[1]</sup>.

As the average life expectancy increases, the population is also aging. This has led to an increased incidence of fractures in geriatric population. Despite the notable improvements in treatment methods, intertrochanteric hip fracture has led to an increased mortality, morbidity and poor outcomes<sup>[4]</sup>. It also puts a significant social and economic burden on patients and healthcare systems<sup>[1]</sup>. In the geriatric population, intertrochanteric fractures

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article

Annals of Medicine & Surgery (2024) 86:703-711

Published online 11 December 2023

are usually the result of low-energy trauma such as a fall from standing height<sup>[5]</sup>.

With an abundant blood supply, intertrochanteric (IT) fractures have a higher union rate and less osteonecrosis compared to femoral neck fracture<sup>[6]</sup>. Additionally, avascular necrosis and nonunion as a result of these fractures is  $uncommon^{[7]}$ . Intertrochanteric fractures are classified as either stable or unstable. A determination of stability is important, as it helps determine the type of fixation required for stability. The posteromedial cortex is intact in stable fractures and reduction would make it resistant to compressive loads. Our decision for surgical treatment is based on the fracture pattern and its inherent stability, as the failure rate is highly correlated with the choice of implant and fracture pattern<sup>[8]</sup>. Fractures with involvement of the lateral femoral wall, displaced lesser trochanter fractures, subtrochanteric extension of the fracture and reverse obliquity fractures are considered to be indications for intramedullary nailing and would not be treated with a sliding hip screw<sup>[9–13]</sup>.

The global number of hip fractures is expected to increase<sup>[14]</sup> and, despite the extensive body of literature regarding fixation of IT fractures, patient functional outcomes remain far from what should be expected. Poor functional outcomes of IT fractures could decrease the quality of life of a patent<sup>[15–17]</sup>.

Our knowledge about the risk factors for intertrochanteric fracture and its association with negative consequences among the geriatric population remains a subject of debate. The purpose of this study was to evaluate and compare the following variables in patients having radiographically confirmed intertrochanteric fracture: demographic data, general condition, type of fracture and treatment of two unstable intertrochanteric femur fracture groups comprising geriatric patients.

#### Material and methods

After acquiring the approval of the institutional ethics committee, we conducted a retrospective study using previously collected data from patients sustaining intertrochanteric fractures. All consecutive patients from November 2016 to September 2020 at our clinic with radiographically confirmed IT fractures were retrospectively included in the study. Patients with a second injury, pathological fractures, bilateral involvement, periprosthetic fractures, those having had previous surgery related to the hip and those with incomplete demographic data or outcome information were excluded. We obtained informed consent from all the participants.

Patient lab data from before and after surgery on post-operation day 1 (POD-1), demographic data, past medical history and information pertaining to the surgery and type of fracture were documented. Lab data before surgery was obtained from the last blood test recorded in the online system when the patient's general condition remained stable from that moment until the time of surgery. The  $\Delta$  variables have been defined as:  $\Delta$  variables = variable on POD-1 – variable before surgery.

The red cell distribution width (RDW) and blood sugar baseline were recorded from the first blood test before surgery. An expert orthopaedic hip surgeon (SHS) determined the type of fracture according to AO/OTA classifications. The study endpoint was defined as the short form-36 score (SF-36) after at least five months of follow-up. SF-36 measurement was carried out by an orthopaedic surgeon by phone contact with patients or their families.

And the study has been reported in line with the STROCSS criteria<sup>[18]</sup>.

#### Statistical analysis

Statistical analysis carried out using SPSS, version 23, for Windows (IBM). Continuous data have been presented as mean  $\pm$  standard deviation. The categorical variables, such as sex, fracture type, surgical technique and smoking history have been summarized as frequencies and percentages. Statistical comparison, when relevant, was performed using a Fisher exact test for the categorical data. Continuous variables were compared using ANOVA, the *t*-test or Mann–Whitney test whenever the data did not appear to have a normal distribution or when the assumption of equal variance was violated across the study groups. An analysis of the multivariable regression modelling was conducted to determine if the baseline parameters were effective for predicting outcomes with confounders present. Multivariate analysis was considered significant at P less than 0.05 and univariate analysis at P less than 0.1. The statistical analysis was carried out in consultation with a statistician.

#### Results

A total of 310 patients were enroled in the study. Information and data were not available for 137 patients due to mortality or having been lost to follow-up. The follow-up duration ranged from 5 to 69.4 months with a mean of  $30.65 \pm 13.96$  months.

#### Demographic variables

The mean age was  $69.62 \pm 14.27$  years at the time of surgery and 45.1% of the patients were female. The baseline parameters of the patients are presented in Table 1. Stable fractures comprised 104 cases and unstable fractures comprised 40 cases.

#### SF-36 scores

The SF-36 scores of patients are summarized in Table 2. The correlations between the quantitative variables and SF-36 are shown in Table 3. Being female (P = 0.062), having diabetes (P = 0.055), thyroid malfunction (P = 0.003), blood transfusion (P = 0.017), prophylactic anticoagulant use (P = 0.064), active cancer (P = 0.010) were risk factors for lower physical functioning (PF).

The social functioning (SF) score was lower in patients with thyroid malfunctions (P = 0.021) and those requiring blood transfusions (P = 0.037). Patients with osteoporosis (P = 0.076) and requiring blood transfusions (P = 0.003) had lower scores for body pain (BP). The physical component summary (PCS) was lower in patients having had blood transfusions (P = 0.088) and patients with active cancer (P = 0.010). The mean score of general health (GH) in those requiring general anaesthesia (P = 0.088) was higher than those requiring both general and spinal anaesthesia simultaneously. The mean score for GH in those requiring general anaesthesia (P = 0.029). Patients requiring prophylactic anticoagulants (P = 0.078) and those with active cancer (P = 0.010) had lower GH scores. The mean score of vitality in those

Table 1           Demographic characteristics	
Characteristics (n = missing)	No. patients, <i>n</i> (%)
Female sex $(n=0)$	78 (45.1)
Age (year; $n = 0$ ) <sup>a</sup>	$69.62 \pm 14.27$
A0/01A (n=2 5)	70 (10.0)
31A1.2	73 (42.2)
31A1.3 21A2.2	31 (17.9)
31A2.2 21A2.2	5(2.0)
31A2.0	J(2.3)
31A3.2	2 (1 2)
31A3.3	10 (6.9)
Smoking $(n = 4)$	55 (31.8)
Height (cm) $(n=24)^{a}$	$166.08 \pm 9.60$
Weight (kg) $(n=23)^a$	68.75 ± 11.17
BMI (kg/m <sup>2</sup> ) $(n = 18)^{a}$	24.937 ± 3.85
Duration of admission to surgery (day) $(n=0)^{a}$	5.20 ± 3.41
Anticoagulant use $(n = 4)$	59 (34.1)
Past medical history	
HTN (n = 0)	72 (41.6)
IHD (n=0)	37 (21.4)
DM(n=0)	41 (23.7)
Thyroid malfunction $(n = 0)$	12 (6.9)
Cancer $(n = 34)$	6 (3.5) 05 (14.5)
Usleoporosis $(7 = 34)$	25 (14.5)
Lab Uala Haemoglobin before surgeny (mg/dl) $(n - 4)^a$	$11.07 \pm 1.86$
$\delta$ haemoglobin (mg/dl) (n = 4)	$-151 \pm 1.00$
Blood sugar before surgery (mg/dl) $(n=31)^a$	$14373 \pm 5268$
$\delta$ blood sugar (mg/dl) ( $n = 96$ ) <sup>a</sup>	-6.04 + 67.70
White blood cell before surgery $(n = 7)^{a}$	$9.30 \pm 2.88$
$\delta$ white blood cell $(n = 70)^{a}$	$1.68 \pm 4.05$
Platelet before surgery $(n=6)^{a}$	
$\delta$ platelet $(n = 70)^{a}$	$26.16 \pm 66.68$
Neutrophil before surgery (%: $n = 9$ ) <sup>a</sup>	$74.56 \pm 9.48$
$\delta$ neutrophil (%: $n = 75$ ) <sup>a</sup>	3.54 <u>+</u> 10.44
Lymphocyte before surgery (%: $n=5$ ) <sup>a</sup>	$16.30 \pm 7.60$
$\Delta$ lymphocyte (%: $n = 71$ ) <sup>a</sup>	$-4.02 \pm 7.60$
Cr before surgery (mg/dl; $n = 15$ ) <sup>a</sup>	$1.15 \pm .52$
$\Delta \text{ Cr } (\text{mg/dl}; n = 91)^{a}$	$-0.03 \pm 0.29$
BUN before surgery $(mg/d); n = 15)^{\alpha}$	$46.72 \pm 21.82$
$\Delta$ BUN (IIIg/dl; $T = 99$ ) <sup>a</sup>	$3.07 \pm 20.74$
Na before surgery (ing/ui; $T = 29$ )	$137.01 \pm 9.27$
$\Delta$ Na (Hig/ul) ( $n = 103$ ) K before surgery (mg/dl) ( $n = 28$ ) <sup>a</sup>	$-0.30 \pm 0.42$
$\Delta$ K (mg/dl: $n = 103$ ) <sup>a</sup>	$0.36 \pm 0.58$
Neutrophil/platelet before surgery $(n=11)^{a}$	$0.034230 \pm 0.0161073$
$\delta$ neutrophil/platelet $(n = 75)^{a}$	0.0034660344 + 0.01617468533
Neutrophil/lymphocyte before surgery $(n = 9)^{a}$	$5.93 \pm 3.42$
$\delta$ neutrophil/lymphocyte ( $n = 76$ ) <sup>a</sup>	$2.22 \pm 4.99$
No. neutrophil before surgery $(n = 11)^a$	$7.10 \pm 2.77$
$\delta$ number of neutrophils $(n = 75)^{a}$	$1.64 \pm 4.00$
No. lymphocytes before surgery $(n=7)^{a}$	$1.43 \pm 0.63$
$\delta$ number of lymphocytes ( $n = 72$ ) <sup>a</sup>	$-0.19 \pm 0.62$
RDW $(n=3)^{a}$	$14.00 \pm 1.87$
Blood sugar baseline (mg/d dl; $n = 35$ ) <sup>a</sup>	$155.92 \pm 73.50$
Surgical factors	
Length of surgery (min; $n = 20)^{a}$	$181.16 \pm 54.00$
Length of time under anaesthesia (min; $n = 1$ ) <sup>a</sup>	$191.72 \pm 53.73$
Anaestitesia type $(I = 1)$	100 /7/ 0
opiriai anacomicola uoc General anacothesia use	120 (14.0) 11 (22 7)
Sninal + general anaesthesia	3 (1 7)
Surgical technique $(n=6)$	0 (1.7)

Table 1	
(Continued)	
Characteristics ( <i>n</i> = missing)	No. patients, <i>n</i> (%)
DHS	143 (82.7)
Arthroplastv	4 (2.3)

Blood transfusion (n = 1) 49 (28.3) BUN, blood urea nitrogen; DCS, dynamic condylar screw; DHS, dynamic hip screw; DM, diabetes mellitus; HTN, hypertension; IHD, ischaemic heart disease; RDW, red cell distribution width. <sup>a</sup>Given as mean  $\pm$  standard deviation.

16 (9.2)

4 (2.3)

requiring spinal anaesthesia was  $8.88 \pm 4.29$  points lower than those requiring both general and spinal anaesthesia simultaneously (*P* = 0.099). The PF was  $32.41 \pm 20.57$  in patients who actively smoked compared to  $25.93 \pm 14.49$  in those who did not smoke (*P* = 0.064).

Role limitations due to physical health was  $34.85 \pm 41.90$  in patients with medical histories of ischaemic heart disease (IHD) compared to  $22.84 \pm 32.06$  in those without IHD (P = 0.069). BP in those with AO/OTA 31A1.2 was  $17.40 \pm 5.31$  points higher than for those with AO/OTA 31A1.3 (P = 0.022). GH in those with AO/OTA 31A1.2 was  $5.87 \pm 1.68$  points higher than for those with AO/OTA 31A1.3 (P = 0.011). GH in those with AO/ OTA 31A1.2 was  $11.75 \pm 3.96$  points higher than for those with AO/OTA 31A3.1 (P = 0.011). GH in those with AO/OTA 31A3.1 (P = 0.011). GH in those with AO/OTA 31A2.2 was  $11.91 \pm 4.24$  points higher than for those with AO/ OTA 31A3.1 (P = 0.081).

The mental component summary (MCS) for those with AO/ OTA 31A1.2 was  $22.99 \pm 7.58$  points lower than for those with AO/OTA 31A3.2 (P = 0.046). The MCS in those with AO/OTA 31A1.3 is  $21.81 \pm 7.73$  points lower than for those with AO/OTA 31A3.2 (P = 0.080). MCS in those with AO/OTA 31A2.3 was  $27.25 \pm 8.83$  points lower than for those with AO/OTA 31A3.2 (P = 0.039).

Duration of admission to surgery,  $\Delta$  blood sugar,  $\Delta$  K, number of lymphocytes before surgery, age, haemoglobin (Hgb) level before surgery, length of time requiring anaesthesia, blood urea nitrogen (BUN) before surgery, white blood count (WBC) before surgery, blood transfusion and cancer were included in the final multivariable regression to predict PCS. The value of R<sup>2</sup> was 0.356. (Table 4). The R<sup>2</sup> value in the multivariable predictive model of MCS was too low and has been omitted.

Table 2

Nail

DCS

SF-36 of patients at medium of 30.65 months follow-up

SF-36 ( <i>n</i> = missing)	Mean (Sd)
Physical functioning (9)	28.29 (17.04)
Role limitations due to physical health (23)	25.17 (34.69)
BP (8)	45.03 (25.18)
General health (9)	40.07 (8.49)
Vitality (8)	55.12 (7.41)
Role limitations due to emotional health (20)	21.78 (40.88)
Mental health (8)	50.59 (7.85)
Social functioning (8)	60.65 (17.20)
PCS (33)	33.83 (7.87)
MCS (33)	20.07 (10.24)

BP, body pain; MCS, mental component summary; PCS, physical component summary; SF-36, short form-36 score.

PF         Role limit due to PH         Body pain         GH         Vital.         SF         Role limit due to ernot. health         MH         PCS         M           Datation of admission to array Produe         0.105         -0.115         -0.115         -0.026         -0.066         -0.062         0.094         -0.216         -0.6           Produe         0.181         0.18         0.175         0.247         0.275         0.401         0.45         0.029         0.017         0.57           Pailes         0.027         0.431         0.019         0.173         0.014         -0.189         -0.074         -0.144         0.218         -0.13           Praises         0.037         0.019         0.173         0.170         0.058         -0.074         -0.144         0.218         -0.14           Praises         0.038         0.452         0.157         0.046         0.0074         0.014         0.048         0.027         -0.148         0.027         -0.144         0.027         0.148         0.028         0.028         0.028         0.028         0.028         0.028         0.028         0.028         0.028         0.028         0.028         0.028         0.028         0.028         0.028	Table 3	SE-36 and qua	antitative variables								
Duration distribution to surgery         -         -         0.016         -         0.017         0.018         0.118         0.118         0.018         0.0247         0.275         0.401         0.45         0.029         0.011         0.05           Pailuan or.         -         0.118         0.118         0.118         0.019         0.021         0.023         0.057         0.021         0.057         0.023         0.056         -         0.092         0.01         0.05           Pailue         0.207         0.481         0.046         0.672         0.124         0.051         -         0.074         -         0.144         0.218         -         0.13         0.128         0.089         -         0.051         -         0.074         -         0.144         0.218         -         0.14         0.218         -         0.13         0.128         0.051         0.051         0.074         0.144         0.218         -         0.051         0.074         0.144         0.218         -         0.074         0.044         0.043         0.051         0.051         0.051         0.051         0.051         0.051         0.051         0.051         0.051         0.051         0.051		PF	Role limit due to PH	Body pain	GH	Vital.	SF	Role limit due to emot. health	МН	PCS	MCS
Person cor.         -0.105         -0.11         -0.015         -0.091         -0.025         -0.062         0.094         -0.215         -0.05           Private         0.181         0.19         0.141         0.44         0.275         0.441         -0.46         0.225         0.003         0.066         -0.022         0.005         -0.037         0.056         -0.037         0.077         0.016         0.072         0.124         0.399         0.973         0.067         0.373         0.77           Pairson cor.         0.067         0.019         0.173         0.126         0.069         -0.0171         -0.142         0.169         -0.076         0.027         -0.144         -0.17           Pairson cor.         0.067         0.019         0.0171         -0.142         -0.167         -0.076         0.027         -0.144         -0.1           Pairson cor.         0.016         0.711         0.173         0.128         -0.052         0.0173         0.027         -0.144         -0.1           Pairson cor.         0.0169         0.027         -0.117         0.016         0.017         0.016         0.017         0.016         0.017         0.017         0.017         0.017         0.017	Duration of admission	on to surgery									
Protein         0.161         0.16         0.178         0.247         0.275         0.401         0.45         0.228         0.011         0.55           Parison cor.         -0.123         0.071         -0.192         0.041         -0.149         -0.003         0.056         -0.092         0.071           A blod staget         Parison cor.         0.067         0.014         0.014         0.048         0.057         0.0233         0.066         -0.073         0.067         0.0233         0.068         0.071           Parison cor.         0.066         -0.071         -0.142         -0.157         -0.045         -0.068         -0.078         0.027         -0.144         -0.071           Parison cor.         -0.046         0.037         -0.065         0.055         0.351         0.461         0.027         -0.144         -0.078           Parison cor.         -0.048         0.031         -0.052         0.052         0.055         0.351         0.366         0.028         0.028         0.028         0.028         0.028         0.028         0.028         0.028         0.026         0.056         0.056         0.056         0.056         0.056         0.056         0.056         0.058	Pearson cor.	- 0.105	- 0.11	- 0.105	- 0.091	- 0.085	- 0.066	- 0.062	0.094	-0.216	- 0.001
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	P value	0.181	0.18	0.178	0.247	0.275	0.401	0.45	0.229	0.01	0.986
Phases nor.         -0.133         0.071         -0.592         0.041         -0.149         -0.082         0.003         0.056         -0.072         0.57 <th< td=""><td><math>\Delta</math> Hgb</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	$\Delta$ Hgb										
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Pearson cor.	-0.123	0.071	- 0.192	0.041	- 0.149	- 0.082	- 0.003	0.056	-0.092	0.027
Δ block signif           Person 0.067         0.014         0.218         0.028         0.057         0.057         0.233         0.068         0.2           Person or.         0.169         0.071         0.142         0.173         0.126         0.065         0.057         0.233         0.068         0.2           Person or.         0.169         0.071         0.142         0.177         0.045         0.065         0.061         0.078         0.014         -0.07           Person or.         0.034         0.031         0.010         0.027         0.062         0.065         0.061         0.078         0.014         -0.04           Person or.         0.036         0.044         0.037         0.062         0.062         0.067         0.061         0.016         0.018         0.018         0.018         0.018         0.018         0.018         0.018         0.018         0.018         0.018         0.018         0.018         0.018         0.018         0.018         0.013         0.01         0.038         0.048         0.049         0.034         0.031         0.01         0.033         0.01         0.033         0.01         0.033         0.01         0.033         0.01	P value	0.207	0.481	0.046	0.672	0.124	0.399	0.973	0.567	0.373	0.796
Person cor.         0.067         0.019         0.173         0.128         0.069         -0.51         -0.074         -0.144         0.218         -0.17           A WBC         -         0.062         -         0.063         -         0.064         -         0.062         0.062         0.063         0.064         -0.063         0.036         0.037         0.037         0.037         0.037         0.037         0.037         0.037         0.037         0.037         0.037         0.037         0.037         0.037         0.037         0.037         0.037         0.037         0.037         0.037         0.038         0.037         0.037 <t< td=""><td><math>\Delta</math> blood sugar</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	$\Delta$ blood sugar										
Produce         0.833         0.883         0.152         0.304         0.568         0.678         0.557         0.233         0.088         0.02           Person cor.         -0.169         -0.071         -0.142         -0.157         -0.065         -0.078         0.085         0.044         0.079	Pearson cor.	0.067	0.019	0.173	0.126	0.069	- 0.051	- 0.074	- 0.144	0.218	- 0.148
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	P value	0.583	0.883	0.152	0.304	0.568	0.678	0.557	0.233	0.088	0.252
Person cor. $-0.169$ $-0.071$ $-0.142$ $-0.045$ $-0.066$ $-0.078$ $0.027$ $-0.146$ $-0.074$ A neatrophil (%)         0.016         0.013 $-0.108$ 0.022 $-0.097$ 0.061 $-0.146$ $-0.077$ Person cor. $-0.248$ 0.03 $-0.108$ 0.022 $-0.097$ 0.061 $-0.146$ $-0.077$ Person cor. $-0.036$ 0.071 $-0.062$ 0.062 $-0.097$ 0.061 $-0.146$ $-0.036$ Paratic cor. $-0.036$ 0.073         0.052         0.544         0.555         0.361         0.56         0.003 $-0.038$ 0.02           Paratic cor. $-0.036$ 0.044 $-0.043$ 0.019         0.038         0.09 $-0.038$ 0.05           A         Paratic         0.051         0.049         0.019         0.038         0.022         0.27         0.315         0.119         9.032         0.922         0.22           A interm cor.         0.018         0.045         0.028         0.055         0.066         0.259	$\Delta$ WBC										
	Pearson cor.	- 0.169	- 0.071	-0.142	- 0.157	- 0.045	- 0.066	- 0.078	0.027	-0.146	- 0.084
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	P value	0.094	0.502	0.158	0.12	0.657	0.515	0.451	0.788	0.174	0.435
Person cor.         -0.248         0.03         -0.108         -0.020         0.062         0.062         0.097         0.061         -0.14         -0.0           A platiel         -         -         -         0.052         0.55         0.361         0.56         0.268         0.55           A platiel         -         -         0.036         0.044         0.043         0.019         0.098         0.09         -0.036         0.01           Praston cor.         -0.056         0.044         0.043         -0.044         -0.043         0.019         0.098         0.09         -0.036         0.01           Pratue         0.726         0.674         0.669         0.673         0.849         0.347         0.373         0.53           A la         -         -         -         0.091         0.254         0.75         0.002         0.207         0.315         0.119         0.932         0.92         0.42           A la         -         -         0.056         0.99         0.12         -0.026         0.078         0.035         0.655         0.497         0.052           Patule         0.366         0.99         0.161         -0.226         0.016	$\Delta$ neutrophil (%)										
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Pearson cor.	- 0.248	0.03	- 0.108	- 0.201	- 0.062	0.062	- 0.097	0.061	-0.14	- 0.067
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	P value	0.016	0.781	0.297	0.052	0.554	0.55	0.361	0.56	0.208	0.546
Person cor.         - 0.036         0.044         0.043         - 0.043         0.019         0.098         0.09         - 0.036         0.07           Pvalue         0.726         0.674         0.669         0.673         0.849         0.347         0.371         0.737         0.67           Parson cor.         - 0.198         0.141         0.038         0.349         - 0.118         0.119         - 0.01         - 0.013         0.1           Parson cor.         - 0.106         0.052         0.048         0.102         - 0.004         0.046         0.259         0.054         - 0.089         0.2           Parson cor.         - 0.106         0.052         0.048         0.102         - 0.004         0.046         0.259         0.054         - 0.089         0.2           Parson cor.         - 0.106         0.052         0.048         0.102         - 0.046         0.259         0.054         - 0.089         0.2           Parson cor.         - 0.102         - 0.021         - 0.221         - 0.128         0.135         - 0.014         0.015         0.154         - 0.077         0.009         0.006         - 0.039         0.00         - 0.036         0.02         0.02         0.02	$\Delta$ platelet										
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Pearson cor.	- 0.036	0.044	0.043	-0.044	- 0.043	0.019	0.098	0.09	- 0.036	0.064
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	P value	0.726	0.674	0.669	0.669	0.673	0.849	0.347	0.371	0.737	0.551
Pearson cor.         -0.198         0.141         0.038         0.349         -0.149         -0.118         0.189         -0.01         -0.013         0.1           Pvalue         0.091         0.254         0.75         0.002         0.07         0.315         0.19         0.932         0.92         0.22           Pearson cor.         -0.106         0.052         0.048         0.102         -0.004         0.046         0.259         0.054         -0.089         0.2           Parson cor.         -0.112         -0.002         -0.189         -0.121         -0.221         -0.128         0.135         -0.01         -0.256         0.1           Parson cor.         -0.112         -0.002         -0.189         -0.121         -0.221         -0.128         0.135         -0.01         -0.256         0.1           Parson cor.         -0.228         0.014         0.015         0.154         -0.007         0.099         0.006         -0.039         0.07           Parson cor.         0.25         -0.066         0.086         0.253         -0.096         0.037         -0.018         0.102         0.7           Parson cor.         0.205         -0.066         0.086         0.225	$\Delta$ Cr										
P value         0.091         0.254         0.75         0.002         0.27         0.315         0.119         0.932         0.92         0.2           A Na	Pearson cor.	- 0.198	0.141	0.038	0.349	- 0.149	- 0.118	0.189	- 0.01	-0.013	0.145
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	P value	0.091	0.254	0.75	0.002	0.207	0.315	0.119	0.932	0.92	0.244
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\Delta$ Na										
P value         0.383         0.686         0.692         0.404         0.976         0.708         0.036         0.655         0.487         0.0           A K         Pearson cor.         -0.112         -0.002         -0.189         -0.121         -0.221         -0.128         0.135         -0.01         -0.256         0.1           P value         0.356         0.99         0.116         0.322         0.006         0.291         0.28         0.937         0.043         0.1           A BIN         Pearson cor.         -0.228         0.014         0.015         0.154         -0.004         -0.077         0.009         0.006         -0.039         0.0           P value         0.05         0.91         0.899         0.193         0.971         0.512         0.938         0.957         0.755         0.75           A lymph. (%)         Pearson cor.         0.226         -0.066         0.263         -0.029         -0.096         0.037         -0.018         0.102         0.0           Pearson cor.         0.209         -0.026         -0.013         0.644         0.02         -0.158         0.0366         -0.079         0.052         0.0         0.0         Parson cor.	Pearson cor.	- 0.106	0.052	0.048	0.102	- 0.004	0.046	0.259	0.054	- 0.089	0.239
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	P value	0.383	0.686	0.692	0.404	0.976	0.708	0.036	0.655	0.487	0.059
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	ΔΚ										
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Pearson cor.	- 0.112	- 0.002	-0.189	-0.121	- 0.221	- 0.128	0.135	- 0.01	- 0.256	0.166
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	<i>P</i> value	0.356	0.99	0.116	0.322	0.065	0.291	0.28	0.937	0.043	0.193
Pearson cor.         -0.228         0.014         0.015         0.154         -0.004         -0.077         0.009         0.006         -0.039         0.00           P value         0.05         0.91         0.899         0.193         0.971         0.512         0.938         0.957         0.755         0.7           Δ lymph. (%)         Pearson cor.         0.25         -0.066         0.086         0.253         -0.029         -0.096         0.037         -0.018         0.102         0.0           P value         0.013         0.532         0.395         0.012         0.779         0.343         0.721         0.858         0.346         0.7           Neutrophil/platelet before surgery         Pearson cor.         0.209         -0.026         -0.013         0.064         0.02         -0.158         0.086         -0.079         0.052         0.0           Pearson cor.         0.034         -0.097         -0.014         0.169         -0.077         -0.072         -0.08         0.036         -0.008         -0.008         -0.008         -0.008         -0.008         -0.008         -0.008         -0.008         -0.008         -0.008         -0.008         -0.008         -0.008         -0.008         -0	$\Delta$ BUN										
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Pearson cor.	- 0.228	0.014	0.015	0.154	- 0.004	-0.077	0.009	0.006	-0.039	0.035
A lymph. (%) Pearson cor.0.025 $-0.066$ 0.0860.253 $-0.029$ $-0.096$ 0.037 $-0.018$ 0.1020.067P value0.0130.5320.3950.0120.7790.3430.7210.8580.3460.77Neutrophil/platelet before surgeryPearson cor.0.209 $-0.026$ $-0.013$ 0.0640.02 $-0.158$ 0.086 $-0.079$ 0.0520.06P value0.0090.7570.8720.4320.8060.0490.3090.3250.5530.4Neutrophil/lymphocyte before surgeryPearson cor.0.034 $-0.097$ $-0.014$ 0.169 $-0.077$ $-0.072$ $-0.08$ 0.036 $-0.008$ $-0.008$ Pearson cor.0.034 $-0.097$ $-0.014$ 0.169 $-0.077$ $-0.072$ $-0.08$ 0.036 $-0.008$ $-0.008$ Pearson cor.0.034 $-0.097$ $-0.014$ 0.169 $-0.077$ $-0.072$ $-0.08$ 0.036 $-0.008$ $-0.008$ Pearson cor. $-0.034$ $-0.097$ $-0.014$ $0.169$ $-0.077$ $-0.072$ $-0.08$ $0.036$ $-0.008$ $-0.008$ Pearson cor. $-0.119$ $-0.026$ $-0.131$ $-0.137$ $0.035$ $-0.109$ $-0.066$ $-0.101$ $-0.078$ $-0.009$ Pearson cor. $-0.15$ $-0.004$ $-0.136$ $-0.161$ $0.001$ $-0.138$ $-0.111$ $-0.062$ $-0.058$ $-0.11$ Pearson cor. $-0.152$ $0.973$ $0.126$ $-$	<i>P</i> value	0.05	0.91	0.899	0.193	0.971	0.512	0.938	0.957	0.755	0.78
Pearson cor. 0.25 -0.066 0.086 0.253 -0.029 -0.096 0.037 -0.018 0.102 0.00 $P$ value 0.013 0.532 0.395 0.012 0.779 0.343 0.721 0.858 0.346 0.7 Neutrophil/platelet before surgery Pearson cor. 0.209 -0.026 -0.013 0.064 0.02 -0.158 0.086 -0.079 0.052 0.00 $P$ value 0.009 0.757 0.872 0.432 0.806 0.049 0.309 0.325 0.553 0.4 Neutrophil/ymphocyte before surgery Pearson cor. 0.034 -0.097 -0.014 0.169 -0.077 -0.072 -0.08 0.036 -0.008 -0.008 -0.0 $P$ value 0.669 0.253 0.858 0.034 0.337 0.369 0.341 0.658 0.931 0.3 $\delta$ neutrophil/platelet Pearson cor0.119 -0.026 -0.131 -0.137 0.035 -0.109 -0.066 -0.101 -0.078 -0.0 $P$ value 0.254 0.808 0.206 0.187 0.735 0.292 0.538 0.33 0.481 0.3 $\delta$ neutrophil/ymph. Pearson cor0.15 -0.004 -0.136 -0.161 0.001 -0.138 -0.111 -0.062 -0.058 -0.1 $P$ value 0.152 0.973 0.193 0.124 0.989 0.185 0.297 0.556 0.601 0.1 $P$ value 0.152 0.973 0.193 0.124 0.989 0.185 0.297 0.556 0.601 0.1	$\Lambda$ lymph. (%)										
P value         0.013         0.532         0.395         0.012         0.779         0.343         0.721         0.858         0.346         0.77           Neutrophil/platelet before surgery         -	Pearson cor.	0.25	-0.066	0.086	0.253	-0.029	- 0.096	0.037	-0.018	0.102	0.029
Neutrophil/platelet before surgery       One of the construction	<i>P</i> value	0.013	0.532	0.395	0.012	0.779	0.343	0.721	0.858	0.346	0.788
Person cor.0.209 $-0.026$ $-0.013$ 0.064 $0.02$ $-0.158$ $0.086$ $-0.079$ $0.052$ $0.079$ Parson cor.0.0090.7570.8720.4320.806 $0.049$ $0.309$ $0.325$ $0.553$ $0.44$ Neutrophil/lymphocyte before surgeryPearson cor.0.034 $-0.097$ $-0.014$ $0.169$ $-0.077$ $-0.072$ $-0.08$ $0.036$ $-0.008$ $-0.026$ P value0.6690.2530.858 $0.034$ 0.337 $0.369$ $0.341$ $0.658$ $0.931$ $0.335$ S neutrophil/plateletPearson cor. $-0.119$ $-0.026$ $-0.131$ $-0.137$ $0.035$ $-0.109$ $-0.066$ $-0.101$ $-0.078$ $-0.078$ Pearson cor. $-0.119$ $-0.026$ $-0.131$ $-0.137$ $0.035$ $-0.109$ $-0.066$ $-0.101$ $-0.078$ $-0.0078$ Pearson cor. $-0.155$ $-0.004$ $-0.136$ $-0.161$ $0.001$ $-0.138$ $-0.111$ $-0.062$ $-0.058$ $-0.11$ VPearson cor. $-0.155$ $-0.004$ $-0.161$ $0.001$ $-0.138$ $-0.111$ $-0.062$ $-0.058$ $-0.11$ Pulle $0.152$ $0.973$ $0.124$ $0.989$ $0.185$ $0.297$ $0.556$ $0.601$ $0.1$	Neutrophil/platelet b	pefore surgery	0.002	0.000	0.012	01110	01010	0.121	0.000	01010	011 00
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Pearson cor.	0.209	-0.026	-0.013	0.064	0.02	- 0.158	0.086	-0.079	0.052	0.059
Neutrophil/lymphocyte before surgery       Onset       Onset <td><i>P</i> value</td> <td>0.009</td> <td>0.757</td> <td>0.872</td> <td>0.432</td> <td>0.806</td> <td>0.049</td> <td>0.309</td> <td>0.325</td> <td>0.553</td> <td>0.499</td>	<i>P</i> value	0.009	0.757	0.872	0.432	0.806	0.049	0.309	0.325	0.553	0.499
Protection of sparsPearson cor. $0.034$ $-0.097$ $-0.014$ $0.169$ $-0.077$ $-0.072$ $-0.08$ $0.036$ $-0.008$ $-0.07$ P value $0.669$ $0.253$ $0.858$ $0.034$ $0.337$ $0.369$ $0.341$ $0.658$ $0.931$ $0.337$ $\delta$ neutrophil/plateletPearson cor. $-0.119$ $-0.026$ $-0.131$ $-0.137$ $0.035$ $-0.109$ $-0.066$ $-0.101$ $-0.078$ $-0.078$ P value $0.254$ $0.808$ $0.206$ $0.187$ $0.735$ $0.292$ $0.538$ $0.33$ $0.481$ $0.33$ $\delta$ neutrophil/ymph.Pearson cor. $-0.15$ $-0.004$ $-0.136$ $-0.161$ $0.001$ $-0.138$ $-0.111$ $-0.062$ $-0.058$ $-0.11$ P value $0.152$ $0.973$ $0.193$ $0.124$ $0.989$ $0.185$ $0.297$ $0.556$ $0.601$ $0.1$	Neutrophil/lymphocy	vte before surgerv		01012	01102	01000	01010	0.000	0.020	01000	01100
P value0.6690.2530.8580.0340.370.3690.3410.6680.9310.5 $\delta$ neutrophil/plateletPearson cor. $-0.119$ $-0.026$ $-0.131$ $-0.137$ $0.035$ $-0.109$ $-0.066$ $-0.101$ $-0.078$ $-0.078$ P value $0.254$ $0.808$ $0.206$ $0.187$ $0.735$ $0.292$ $0.538$ $0.33$ $0.481$ $0.33$ $\delta$ neutrophil/lymph.Pearson cor. $-0.15$ $-0.004$ $-0.136$ $-0.161$ $0.001$ $-0.138$ $-0.111$ $-0.062$ $-0.058$ $-0.11$ P value $0.152$ $0.973$ $0.193$ $0.124$ $0.989$ $0.185$ $0.297$ $0.556$ $0.601$ $0.101$	Pearson cor	0.034	- 0.097	-0.014	0.169	-0.077	-0.072	-0.08	0.036	-0.008	-0.078
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	P value	0.669	0.253	0.858	0.034	0.337	0.369	0.341	0.658	0.931	0.371
Pearson cor. $-0.119$ $-0.026$ $-0.131$ $-0.137$ $0.035$ $-0.109$ $-0.066$ $-0.101$ $-0.078$ $-0.078$ P value $0.254$ $0.808$ $0.206$ $0.187$ $0.735$ $0.292$ $0.538$ $0.33$ $0.481$ $0.33$ $\delta$ neutrophil/lymph. $Pearson cor.$ $-0.15$ $-0.004$ $-0.136$ $-0.161$ $0.001$ $-0.138$ $-0.111$ $-0.062$ $-0.058$ $-0.1$ P value $0.152$ $0.973$ $0.193$ $0.124$ $0.989$ $0.185$ $0.297$ $0.556$ $0.601$ $0.1$	$\delta$ neutrophil/nlatelet	t 0.000	0.200	0.000	0.007	0.007	0.000	0.011	0.000	0.007	0.071
P value         0.254         0.808         0.206         0.187         0.735         0.292         0.538         0.33         0.481         0.3 $\delta$ neutrophil/ymph.         Pearson cor. $-0.15$ $-0.004$ $-0.136$ $-0.161$ $0.001$ $-0.138$ $-0.111$ $-0.062$ $-0.058$ $-0.1$ $P$ value $0.152$ $0.973$ $0.193$ $0.124$ $0.989$ $0.185$ $0.297$ $0.556$ $0.601$ $0.1$	Pearson cor	-0119	-0.026	-0.131	-0137	0.035	-0109	-0.066	-0101	-0.078	- 0 095
$\delta$ neutrophil/lymph.       0.107       0.107       0.108       0.122       0.000       0.101       0.101         Pearson cor.       -0.15       -0.004       -0.136       -0.161       0.001       -0.138       -0.111       -0.062       -0.058       -0.1         P value       0.152       0.973       0.193       0.124       0.989       0.185       0.297       0.556       0.601       0.1	P value	0.254	0.808	0.206	0.187	0.735	0.292	0.538	0.33	0.481	0.000
Pearson cor.         -0.15         -0.004         -0.136         -0.161         0.001         -0.138         -0.111         -0.062         -0.058         -0.1           P value         0.152         0.973         0.193         0.124         0.989         0.185         0.297         0.556         0.601         0.1	δ neutrophil/lvmnh	0.204	0.000	0.200	0.107	0.100	0.202	0.000	0.00	0.101	0.000
P value         0.152         0.973         0.193         0.124         0.989         0.185         0.297         0.556         0.601         0.1	Pearson cor	-015	_ 0 004	_0136	_0 161	0.001	_ 0 138	_0111	_ 0.062	_ 0.058	_01/2
n national before auropau	P value	0 152	0.004	0.100	0.124	0.001	0.185	0 297	0.556	0.601	0.143
	No neutronhil before		0.010	0.100	0.127	0.000	0.100	0.201	0.000	0.001	0.157

Annals of Medicine & Surgery

Pearson cor.	0.12	- 0.06	0.133	0.222	0.042	- 0.035	- 0.003	- 0.081	0.131	- 0.028
P value	0.138	0.48	0.098	0.006	0.602	0.664	0.969	0.318	0.134	0.747
No. lymphocyte befo	ore surgery									
Pearson cor.	0.094	0.119	0.166	- 0.035	0.173	0.189	0.124	- 0.025	0.147	0.126
P value	0.243	0.155	0.036	0.661	0.029	0.017	0.136	0.751	0.09	0.146
δ no. neutrophil										
Pearson cor.	- 0.182	- 0.032	-0.143	- 0.188	- 0.028	- 0.053	- 0.066	0.024	-0.14	- 0.074
P value	0.08	0.77	0.166	0.069	0.787	0.61	0.536	0.818	0.208	0.508
δ no. lymphocyte										
Pearson cor.	0.063	- 0.109	0.034	0.158	- 0.088	- 0.056	-0.042	0.031	0.011	- 0.048
P value	0.539	0.302	0.741	0.123	0.388	0.584	0.686	0.763	0.921	0.659
Age										
Pearson cor.	- 0.418	-0.114	- 0.542	- 0.381	- 0.3	- 0.27	- 0.009	0.13	- 0.548	0.062
P value	0	0.164	0	0	0	0	0.913	0.096	0	0.47
Hgb before surgery										
Pearson cor.	0.216	- 0.086	0.245	0.142	0.114	0.137	-0.028	- 0.047	0.182	- 0.082
P value	0.006	0.299	0.002	0.072	0.15	0.083	0.737	0.551	0.034	0.342
Blood sugar baseline	е									
Pearson cor.	- 0.071	- 0.093	- 0.057	0.096	- 0.112	0.003	- 0.067	0.136	- 0.092	0.036
P value	0.425	0.322	0.521	0.278	0.203	0.972	0.466	0.122	0.348	0.711
Blood sugar before a	surgery									
Pearson cor.	- 0.067	- 0.038	- 0.031	0.06	- 0.035	- 0.071	0.005	0.073	- 0.089	0.071
P value	0.445	0.681	0.719	0.49	0.684	0.414	0.953	0.401	0.352	0.454
Anaesthesia time										
Pearson cor.	- 0.153	- 0.164	- 0.005	- 0.031	0.009	0.074	- 0.07	0.059	- 0.158	0.007
P value	0.051	0.045	0.947	0.694	0.906	0.349	0.395	0.454	0.063	0.932
Operation time										
Pearson cor.	-0.113	- 0.082	0.02	- 0.088	0.058	0.088	- 0.043	0.056	- 0.07	0.034
P value	0.177	0.353	0.815	0.297	0.486	0.295	0.62	0.505	0.443	0.708
Height										
Pearson cor.	0.155	0.073	0.095	0.145	0.01	0.05	0.105	0.037	0.114	0.099
P value	0.064	0.407	0.258	0.085	0.904	0.555	0.229	0.663	0.211	0.277
Weight										
Pearson cor.	0.128	0.027	0.049	- 0.087	- 0.054	0.055	0.006	0.1	0.068	0.031
P value	0.126	0.755	0.559	0.302	0.518	0.509	0.944	0.235	0.455	0.736
BMI										
Pearson cor.	0.009	- 0.037	- 0.033	- 0.177	- 0.092	- 0.001	- 0.093	0.078	- 0.021	- 0.056
P value	0.917	0.673	0.691	0.031	0.267	0.987	0.279	0.342	0.818	0.536
Platelet before surge	ery									
Pearson cor.	- 0.073	- 0.047	0.167	0.111	0.028	0.152	- 0.093	0.016	0.089	- 0.102
P value	0.366	0.575	0.036	0.164	0.731	0.056	0.262	0.837	0.305	0.238
Neutrophil before su	irgery (%)									
Pearson cor.	0.011	- 0.097	- 0.045	0.175	- 0.059	- 0.188	- 0.068	- 0.079	0.001	- 0.099
P value	0.891	0.253	0.572	0.029	0.46	0.018	0.419	0.322	0.992	0.254
Lymphocyte before	surgery (%)									
Pearson cor.	0.008	0.134	0.073	- 0.101	0.093	0.17	0.084	0.01	0.057	0.087
P value	0.92	0.107	0.355	0.206	0.241	0.031	0.308	0.901	0.506	0.313
Cr before surgery	0.117	0.004	0.000	0.004	0.001	0.014	0.110		0.014	A 405
Pearson cor.	-0.117	0.094	0.002	0.024	- 0.031	0.014	0.113	0.119	- 0.014	0.167
P value	0.155	0.278	0.981	0.771	0.706	0.864	0.186	0.147	0.874	0.061

Ramezani et al. Annals of Medicine & Surgery (2024)

		Dele limit due to DU	Doth: soils	Ð	VET	Ę	Dele limit due to const health	MM	200	JOW
	2	KOIE IIIIII aue lo FD	bouy pain	5	VILAI.	P	ROIE IITIIL QUE LO EMOL. REALLI	ШM	3	MICS
BUN before surgery										
Pearson cor.	- 0.206	- 0.005	- 0.212	- 0.096	- 0.222	- 0.053	0.078	0.225	- 0.187	0.107
P value	0.012	0.951	0.00	0.242	0.006	0.515	0.363	0.006	0.036	0.231
Na before surgery										
Pearson cor.	0.081	- 0.012	- 0.067	- 0.105	- 0.037	- 0.106	0.05	- 0.064	- 0.054	0.025
P value	0.348	0.897	0.432	0.223	0.666	0.216	0.58	0.457	0.568	0.792
K before surgery										
Pearson cor.	- 0.034	0.146	0.025	0.006	- 0.04	- 0.145	0.102	0.021	0.096	0.057
P value	0.694	0.108	0.774	0.944	0.643	0.088	0.255	0.81	0.308	0.543
RDW										
Pearson cor.	-0.133	0.165	- 0.071	- 0.097	- 0.067	- 0.022	0.154	0.064	- 0.066	0.145
P value	0.094	0.046	0.369	0.223	0.394	0.781	0.059	0.418	0.443	0.091
WBC before surgery										
Pearson cor.	0.151	- 0.034	0.17	0.182	0.083	0.022	0.021	- 0.066	0.16	0.01
P value	0.06	0.687	0.032	0.022	0.295	0.779	0.797	0.409	0.065	0.91

# Discussion

With the rapid aging of the population, a trend toward an increase in the incidence of hip fractures, including intertrochanteric fractures, is being observed. There are different opinions about the factors affecting functional outcomes, especially in elderly patients. This study investigated the correlations between postoperative variables, their changes and functional outcomes after surgery.

The results of previous studies have indicated that factors such as the age, pre-fracture function of the patient, comorbidities, fracture type, anaemia, dementia, muscle strength and early mobilization can influence functional outcomes after a hip fracture<sup>[19,20]</sup>. A negative correlation between the duration of admission to surgery and PCS was found in our study. Previous studies have suggested that a delay in surgery is associated with worse functional outcomes<sup>[21,22]</sup>. Previous studies indicated that patients who underwent surgery earlier, recovered weightbearing capacity and self-care ability faster than those who had delayed surgery<sup>[23,24]</sup>.

Prescribing anticoagulants for patients with a hip fracture can impose a delay in surgical fixation<sup>[25]</sup>. However, our results revealed that patients given prophylactic anticoagulants had lower GH and PF scores than patients who did not receive anticoagulants. IT fracture itself appears to be an independent risk factor for poorer hip function<sup>[26]</sup>. Hypertension and anaemia are also among the most common comorbidities in patients with hip fracture<sup>[27]</sup>.

Our results demonstrated that a higher Hgb level before surgery is associated with better PCS, PF, BP, GH and SF scores. One meta-analysis reported that anaemia upon admission was found to be associated with poor functional outcomes and that people with low Hgb levels upon admission were more likely to be frail and have less muscle strength than those without anaemia<sup>[28]</sup>. Atthakomol *et al.*<sup>[29]</sup>. reported that the Hgb level upon admission was a prognostic factor for functional outcomes and mortality in patients with hip fracture.

In contrast with the results of a previous study<sup>[30]</sup>, postoperative Hgb levels failed to show any correlation with SF-36, although a change in Hgb seemed to worsen body pain. It has been shown that perioperative blood loss is correlated with an increased risk of mortality, infection, deep vein thrombosis and poorer functional outcomes<sup>[31,32]</sup>. However, blood loss did not correlate with SF-36 scores in our study, although transfused patients had lower scores for PF, BP, PCS and SF.

In both diabetic and non-diabetic patients, the glucose levels before and after surgery had no correlation with SF-36, although SF seemed to have a weak correlation with glucose level before surgery in non-diabetic patients. However, the mean SF-36 scores for diabetic and non-diabetic patients were similar and no association was found between being diabetic and SF-36 scores except that PF scores tended to be lower in diabetic patients. Some studies have indicated that diabetic patients have poorer rehabilitation and functional outcomes than non-diabetic patients<sup>[33,34]</sup>, but other studies have concluded that functional outcomes after hip fracture was not affected by diabetes<sup>[35]</sup>.

Our results also showed a correlation between the BUN levels before surgery and SF-36 for PF, BP, vitality, mental health (MH) and PCS. BUN/Cr before surgery also showed a correlation with BP, vitality, MH and PCS. We found a positive correlation between WBC before surgery and SF scores for PF, BP, GH and

Table 4	
Regression	model of PCS

			coefficients				95.0%	CI for B
Model		В	Std. error	Beta	t	Р	Lower bound	Upper bound
	(Constant)	43.996	19.182		2.294	0.029	4.764	83.227
	Duration of admission to surgery	- 0.642	0.36	- 0.335	- 1.784	0.085	- 1.378	0.094
	$\Delta$ Blood sugar	0.03	0.023	0.219	1.297	0.205	-0.017	0.077
	ΔΚ	- 2.172	2.146	- 0.17	- 1.012	0.32	- 6.562	2.217
	No lymphocyte before surgery	1.735	1.624	0.178	1.068	0.294	- 1.587	5.058
	Age	- 0.101	0.118	- 0.15	- 0.849	0.403	- 0.343	0.142
	Hgb before surgery	0.321	0.869	0.087	0.37	0.714	-1.455	2.098
	Anaesthesia time	0.002	0.021	0.016	0.093	0.927	- 0.042	0.046
	BUN before surgery	0.026	0.074	0.068	0.354	0.726	- 0.125	0.177
	WBC before surgery	- 0.706	0.495	- 0.299	- 1.427	0.164	- 1.717	0.306
	Blood transfusion	- 0.533	2.903	- 0.04	- 0.184	0.856	- 6.47	5.403
	Cancer	- 3.929	3.527	- 0.173	- 1.114	0.274	- 11.142	3.285
Model su	mmary							
Model	R	R <sup>2</sup>	Adj. R <sup>2</sup>	Std. error of estimate				
1	0.597 <sup>a</sup>	0.356	0.112	6.42612				

(Constant): cancer,  $\Delta$  K,  $\Delta$  blood sugar, no. of lymphocyte before surgery, age, duration of admission to surgery, anaesthesia time, BUN before surgery, WBC before surgery, blood transfusion, Hgb before surgery.

BUN, blood urea nitrogen; Hgb, haemoglobin; PCS, physical component summary; WBC, white blood count.

PCS. The immune response being known in order to limit infection might influence functional outcomes<sup>[36]</sup>. The number of platelets also correlated with better BP and vitality scores. The current study identified lower levels of neutrophil and neutrophil/ lymphocyte as being associated with lower GH scores. The lymphocyte count before surgery also correlated with BP, vitality, SF and PCS.

Previous health, functional status and social circumstances have been shown to be associated with functional outcomes in elderly patients with hip fractures<sup>[37,38]</sup>. Establishing a proper communication, even through the phone, with the patient might benefit them, such as better self-care and well-being<sup>[39–41]</sup>. In line with previous studies<sup>[42]</sup>, we found that advanced age correlated strongly with lower scores for PF, BP, GH, vitality, SF and PCS. However, a weak correlation was found between advanced age and better MH scores. No clear cutoff value for age has been determined.

The mean PF scores was higher for males than for females in our study. This is in contrast with previous studies which indicated that males generally tended to have worse outcomes<sup>[43–46]</sup>. Our results support results from previous studies that indicate that a previous health history of thyroid malfunction (PF and SF), cancer (PF, GH and PCS), osteoporosis (BP) and smoking (PF) worsened SF-36 scores. Although no association was found between the length of the surgery and SF-36 scores, but regarding anaesthetic time, lower anaesthetic time was correlated with better PF, role limitations due to physical health and PCS scores.

Some studies found differences in postoperative cognitive dysfunction between general and spinal anaesthesia in elderly patients<sup>[47–49]</sup>, while other studies indicated no differences in the effect of anaesthesia type on postoperative cognitive dysfunction<sup>[43,50–52]</sup>. We found that the GH score was higher after general anaesthesia alone compared to spinal alone and combined use of spinal and general anaesthesia.

Among the variables investigated in this study, lab data and demographic characteristics including higher WBC before surgery, BUN before surgery, Cr before surgery,  $\Delta$  Number of

Neutrophiles, lower Haemoglobin levels before surgery, K before surgery, being female, older age, history of IHD, having diabetes mellitus, longer duration of admission to surgery and blood transfusion have been identified as key factors in predicting in-hospital or long-term mortality rates in another study<sup>[53]</sup>.

In our study, AO/OTA classification was not associated with any SF-36 sub-scores. A study by Chehade *et al.*<sup>[54]</sup>. showed that unstable fractures according to AO/OTA were accompanied by early device failure that required reoperation and mortality after trochanteric hip fractures. It should also be considered that the surgical method employed and its proper execution affects the subsequent outcomes<sup>[55]</sup>. Several studies comparing the gamma nail and DHS have indicated that DHS seems to be a better method for treatment of trochanteric fractures<sup>[56,57]</sup>. Other studies have found no noteworthy differences, including functional outcomes, between these two methods<sup>[58–60]</sup>.

# Strengths and limitations

One strength of our study was that it was one of only a few to clarify the association between pre-operative factors and SF-36 scores in elderly patients with IT fractures. One limitation of the study was the retrospective collection of baseline characteristics of patients, which make it susceptible to several types of bias. Also, because of the lack of randomization, we cannot infer causal effects. Additionally, we did not have a standardized method of assessing the presence of comorbid conditions. For example, determination of the presence of diabetes or osteoporosis were based on the self-reported symptoms. Also, as older patients are more prone to cognitive dysfunction and lack of recall, some information could be lacking. Finally, only one surgeon computed the SF-36 scores, which could have affected their accuracy. Telephone interviews also might have been influenced by interviewer bias.

#### Conclusion

In summary, delayed surgery, anaemia, BUN, BUN/Cr ratio, compromised immune system, advanced age and longer exposure time to anaesthesia were associated with lower SF-36 scores. The factors of female gender, advanced age, history of diabetes, thyroid malfunction, cancer, osteoporosis, prophylactic anticoagulant use, combined use of general and spinal anaesthesia and blood transfusions also were found to correlate with reduced SF-36 scores. It is evident that patient-related factors and perioperative factors should be considered carefully when treating IT fractures. Considering these findings, we suggest that individual treatment should be applied for each patient based on fracture type and any other underlying risk factors to mitigate the interference of modifiable factors.

Further large-scale, well-designed, sufficiently powered randomized controlled trials would be needed to validate our findings.

#### **Ethical approval**

The present study design was approved by the Research Ethics Committees of Sina Hospital, Tehran University of Medical Sciences (Code: IR.TUMS.SINAHOSPITAL.REC.1400.084) on 26 October 2021.

# Consent

No personal information or images of the patients have been used in this study. Written informed consent was obtained from the patients for publication and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

#### Source of funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

### **Author contribution**

S.H.S.: conceptualization and review. A.R.: writing the manuscript and analysing data. M.B.: data gathering and writing the manuscript. A.G.R.: editing the manuscript. M.G.: analysing data.

# **Conflicts of interest disclosure**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

# Research registration unique identifying number (UIN)

- 1. Name of the registry: A. Research Proposal Information System. B. Iran National Committee for Ethics in Biomedical Research.
- 2. Unique identifying number or registration ID: A. 54506. B. IR.TUMS.SINAHOSPITAL.REC.1400.084.

 Hyperlink to your specific registration (must be publicly accessible and will be checked): A. https://rpis.research.ac.ir/ Researcher.php?id=3194820 B. http://ethics.research.ac.ir/ IR.TUMS.SINAHOSPITAL.REC.1400.084.

#### Guarantor

Dr seyyed Hossein shafiei as the corresponding author accepts full responsibility for this work.

#### **Data availability statement**

All the data are available with the corresponding author.

#### Provenance and peer review

Not commissioned, externally peer-reviewed.

#### References

- Adeyemi A, Delhougne G. Incidence and economic burden of intertrochanteric fracture: a medicare claims database analysis. JB & JS open access 2019;4:e0045.
- [2] Attum B, Pilson H. Intertrochanteric Femur Fracture. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright ©; 2022StatPearls Publishing LLC; 2022.
- [3] Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world-wide projection. Osteop Int 1992;2:285–9.
- [4] Kesmezacar H, Ayhan E, Unlu MC, et al. Predictors of mortality in elderly patients with an intertrochanteric or a femoral neck fracture. J Trauma 2010;68:153–8.
- [5] Chen PH, Wu CC, Chen WJ. Factors affect stability of intertrochanteric fractures when elderly patients fall. Biomed J 2016;39:67–71.
- [6] Sharma A, Sethi A, Sharma S. Treatment of stable intertrochanteric fractures of the femur with proximal femoral nail versus dynamic hip screw: a comparative study. Revista Brasileira de Ortopedia 2018;53: 477–81.
- [7] Mont MA, Hungerford DS. Non-traumatic avascular necrosis of the femoral head. JBJS 1995;77:459–74.
- [8] Kyle RF, Gustilo RB, Premer RF. Analysis of six hundred and twenty-two intertrochanteric hip fractures. J Bone Joint Surg Am Vol 1979;61: 216–21.
- [9] Im G-I, Shin Y-W, Song Y-J. Potentially unstable intertrochanteric fractures. J Orthop Trauma 2005;19:5–9.
- [10] Palm H, Jacobsen S, Sonne-Holm S, *et al.* Integrity of the lateral femoral wall in intertrochanteric hip fractures: an important predictor of a reoperation. JBJS 2007;89:470–5.
- [11] Pelet S, Arlettaz Y, Chevalley F. Osteosynthesis of per-and subtrochanteric fractures by blade plate versus gamma nail. A randomized prospective study. Swiss Surg 2001;7:126–33.
- [12] Sadowski C, Lübbeke A, Saudan M, et al. Treatment of reverse oblique and transverse intertrochanteric fractures with use of an intramedullary nail or a 95 screw-plate: a prospective, randomized study. JBJS 2002;84: 372–81.
- [13] Kregor PJ, Obremskey WT, Kreder HJ, et al. Unstable pertrochanteric femoral fractures. J Orthop Trauma 2005;19:63–6.
- [14] Wade SW, Strader C, Fitzpatrick LA, et al. Sex- and age-specific incidence of non-traumatic fractures in selected industrialized countries. Arch Osteop 2012;7:219–27.
- [15] Jamal Sepah Y, Umer M, Khan A, et al. Functional outcome, mortality and in-hospital complications of operative treatment in elderly patients with hip fractures in the developing world. Int Orthop 2010;34:431–5.
- [16] Cornwall R, Gilbert MS, Koval KJ, et al. Functional outcomes and mortality vary among different types of hip fractures: a function of patient characteristics. Clin Orthop Relat Res 2004;425:64–71.
- [17] Sernbo I, Johnell O. Background factors in patients with hip fracturesdifferences between cervical and trochanteric fractures. Comprehens Gerontol Sect A, Clin Lab Sci 1987;1:109–11.

- [18] Mathew G, Agha R, Albrecht J, et al. STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. Int J Surg (London, England) 2021;96:106165.
- [19] Takayama S, Iki M, Kusaka Y, *et al.* Factors that influence functional prognosis in elderly patients with hip fracture. Environ Health Prevent Med 2001;6:47–53.
- [20] Koval KJ, Skovron ML, Aharonoff GB, et al. Predictors of functional recovery after hip fracture in the elderly. Clin Orthop Relat Res 1998; 348:22–8.
- [21] Song J, Zhang G, Liang J, et al. Effects of delayed hip replacement on postoperative hip function and quality of life in elderly patients with femoral neck fracture. BMC Musculoskelet Disord 2020;21:487–.
- [22] Butler A, Hahessy S, Condon F. The effect of time to surgery on functional ability at six weeks in a hip fracture population in Mid-West Ireland. Int J Orthop Trauma Nursing 2017;26:36–42.
- [23] Cha YH, Ha YC, Yoo JI, et al. Effect of causes of surgical delay on early and late mortality in patients with proximal hip fracture. Arch Orthop Trauma Surg 2017;137:625–30.
- [24] Jain H, Garg S, Yadav S, et al. Functional outcome of old fracture neck of femur treated by double angle DHS with valgus osteotomy with fibular grafting. Int J Contemp Med Res 2017;4:1975.
- [25] You D, Xu Y, Ponich B, et al. Effect of oral anticoagulant use on surgical delay and mortality in hip fracture. Bone Joint J 2021103-b, 2:222–33.
- [26] Martín-Martín LM, Arroyo-Morales M, Sánchez-Cruz JJ, et al. Factors influencing performance-oriented mobility after hip fracture. J Aging Health 2015;27:827–42.
- [27] Nikkel LE, Fox EJ, Black KP, et al. Impact of comorbidities on hospitalization costs following hip fracture. J Bone Joint Surg Am Vol 2012;94: 9–17.
- [28] Sheehan KJ, Williamson L, Alexander J, et al. Prognostic factors of functional outcome after hip fracture surgery: a systematic review. Age Ageing 2018;47:661–70.
- [29] Atthakomol P, Manosroi W, Phinyo P, et al. Prognostic factors for allcause mortality in thai patients with fragility fracture of hip: comorbidities and laboratory evaluations. Medicina 2020;56:311.
- [30] Lawrence VA, Silverstein JH, Cornell JE, et al. Higher Hb level is associated with better early functional recovery after hip fracture repair. Transfusion 2003;43:1717–22.
- [31] Wang J, Wei J, Wang M. The risk factors of perioperative hemoglobin and hematocrit drop after intramedullary nailing treatment for intertrochanteric fracture patients. J Orthop Sci 2015;20:163–7.
- [32] Seyedi HR, Mahdian M, Khosravi G, et al. Prediction of mortality in hip fracture patients: role of routine blood tests. Arch Bone Joint Surg 2015; 3:51–5.
- [33] Yoon SH, Kim BR, Lee SY, et al. Influence of comorbidities on functional outcomes in patients with surgically treated fragility hip fractures: a retrospective cohort study. BMC Geriatr 2021;21:283.
- [34] Lieberman D, Friger M, Lieberman D. Rehabilitation outcome following hip fracture surgery in elderly diabetics: a prospective cohort study of 224 patients. Disabil Rehabilitat 2007;29:339–45.
- [35] Tian W, Wu J, Tong T, et al. Diabetes and risk of post-fragility hip fracture outcomes in elderly patients. Int J Endocrinol 2020;2020: 8146196-.
- [36] Basile G, Gallina M, Passeri A, et al. Prosthetic joint infections and legal disputes: a threat to the future of prosthetic orthopedics. J Orthop Traumatol 2021;22:44.
- [37] Koval KJ, Skovron ML, Aharonoff GB, *et al*. Ambulatory ability after hip fracture. A prospective study in geriatric patients. Clin Orthop Relat Res 1995;310:150–9.
- [38] Vergara I, Vrotsou K, Orive M, et al. Factors related to functional prognosis in elderly patients after accidental hip fractures: a prospective cohort study. BMC Geriatr 2014;14:124.
- [39] Marinelli S, Basile G, Zaami S. Telemedicine, Telepsychiatry and COVID-19 Pandemic: Future Prospects for Global Health. Healthcare 2022;10:2085.

- [40] Basile G, Accetta R, Marinelli S, et al. Traumatology: Adoption of the Sm@rtEven Application for the Remote Evaluation of Patients and Possible Medico-Legal Implications. J Clin Med 2022;11:3644.
- [41] Basile G. The autobiographical narrative as a damage assessment means: injuries to profound subjective sensitivities - personalization and objectivization of medicolegal relevance. La Clin Terap 2022;173:585–9.
- [42] Hu F, Jiang C, Shen J, et al. Preoperative predictors for mortality following hip fracture surgery: a systematic review and meta-analysis. Injury 2012;43:676–85.
- [43] Orwig DL, Chan J, Magaziner J. Hip fracture and its consequences: differences between men and women. Orthop Clin North Am 2006;37: 611–22.
- [44] Endo Y, Aharonoff GB, Zuckerman JD, et al. Gender differences in patients with hip fracture: a greater risk of morbidity and mortality in men. J Orthop Trauma 2005;19:29–35.
- [45] Hawkes WG, Wehren L, Orwig D, et al. Gender differences in functioning after hip fracture. J Gerontol Ser A Biol Sci Med Sci 2006;61: 495–9.
- [46] Holt G, Smith R, Duncan K, et al. Gender differences in epidemiology and outcome after hip fracture. J Bone Joint Surg Br Vol 2008;90-B:480–3.
- [47] Rasmussen LS, Johnson T, Kuipers HM, et al. Does anaesthesia cause postoperative cognitive dysfunction? A randomised study of regional versus general anaesthesia in 438 elderly patients. Acta Anaesthesiol Scand 2003;47:260–6.
- [48] Papaioannou A, Fraidakis O, Michaloudis D, et al. The impact of the type of anaesthesia on cognitive status and delirium during the first postoperative days in elderly patients. Eur J Anaesthesiol 2005;22:492–9.
- [49] Anwer HM, Swelem SE, el-Sheshai A, et al. Postoperative cognitive dysfunction in adult and elderly patients--general anesthesia vs subarachnoid or epidural analgesia. Middle East J Anaesthesiol 2006;18: 1123–38.
- [50] Riis J, Lomholt B, Haxholdt O, *et al.* Immediate and long-term mental recovery from general versus epidural anesthesia in elderly patients. Acta Anaesthesiol Scand 1983;27:44–9.
- [51] Williams-Russo P, Sharrock NE, Mattis S, et al. Cognitive effects after epidural vs general anesthesia in older adults. A randomized trial. JAMA 1995;274:44–50.
- [52] Ghoneim MM, Hinrichs JV, O'Hara MW, et al. Comparison of psychologic and cognitive functions after general or regional anesthesia. Anesthesiology 1988;69:507–15.
- [53] Babagoli M, Ghaseminejad Raeini A, Sheykhvatan M, et al. Influencing factors on morbidity and mortality in intertrochanteric fractures. Sci Rep 2023;13:12090.
- [54] Chehade MJ, Carbone T, Awwad D, et al. Influence of fracture stability on early patient mortality and reoperation after pertrochanteric and intertrochanteric hip fractures. J Orthop Trauma 2015;29:538–43.
- [55] Basile G, Fozzato S, Petrucci QA, et al. Treatment of femoral shaft pseudarthrosis, case series and medico-legal implications. J Clin Med 2022;11:7407.
- [56] Radford PJ, Needoff M, Webb JK. A prospective randomised comparison of the dynamic hip screw and the gamma locking nail. J Bone Joint Surg Br Vol 1993;75:789–93.
- [57] Parker MJ, Pryor GA. Gamma versus DHS nailing for extracapsular femoral fractures. Meta-analysis of ten randomised trials. Int Orthop 1996;20:163–8.
- [58] Saarenpää I, Heikkinen T, Ristiniemi J, et al. Functional comparison of the dynamic hip screw and the Gamma locking nail in trochanteric hip fractures: a matched-pair study of 268 patients. Int Orthop 2009;33: 255–60.
- [59] Leung KS, So WS, Shen WY, et al. Gamma nails and dynamic hip screws for peritrochanteric fractures. A randomised prospective study in elderly patients. J Bone Joint Surg Br Vol 1992;74:345–51.
- [60] Goldhagen PR, O'Connor DR, Schwarze D, et al. A prospective comparative study of the compression hip screw and the gamma nail. J Orthop Trauma 1994;8:367–72.